BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Clinical Outcome
302 results:

  • 1. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
    Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Emilin2 fosters vascular stability by promoting pericyte recruitment.
    Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
    Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
    Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
    Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
    McHenry A; Rottmann DA; Buza N; Hui P
    Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
    Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
    Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
    Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
    BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
    Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
    J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade ovarian Serous Carcinoma.
    Ruano APC; Gadelha Guimarães AP; Braun AC; Flores BCTCP; Tariki MS; Abdallah EA; Torres JA; Nunes DN; Tirapelli B; de Lima VCC; Fanelli MF; Colombo PE; da Costa AABA; Alix-Panabières C; Chinen LTD
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499015
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Is microcystic, elongated, and fragmented pattern of myometrial invasion in endometrioid endometrial carcinoma associated with survival?
    Altındağ SD; Yiğit S; Şen S
    Turk J Med Sci; 2022 Oct; 52(5):1569-1579. PubMed ID: 36422476
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
    Konaté MM; Li MC; McShane LM; Zhao Y
    Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
    [TBL] [Abstract] [Full Text] [Related]  

  • 12.
    Bjersand K; Blom K; Poromaa IS; Stålberg K; Lejon AM; Bäckman F; Nyberg Å; Andersson C; Larsson R; Nygren P
    Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 36082820
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. clinical outcome of embryo cryopreservation in Japanese breast cancer patients: pregnancy rates after transfer of thawed embryos.
    Okutsu-Horage Y; Iwahata H; Suzuki-Takahashi Y; Sugishita Y; Takae S; Suzuki N
    J Assist Reprod Genet; 2022 Aug; 39(8):1769-1777. PubMed ID: 35980490
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
    Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K
    Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience.
    Kim MS; Jeong SY; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
    Taiwan J Obstet Gynecol; 2022 Mar; 61(2):333-338. PubMed ID: 35361397
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Response to Chemotherapy and clinical outcome of Patients With Recurrent Epithelial ovarian cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
    Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. CTLA-4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer.
    Chen J; Kang S; Wu J; Zhao J; Si W; Sun H; Li Y
    J Obstet Gynaecol Res; 2022 May; 48(5):1240-1247. PubMed ID: 35150042
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.
    Devereaux KA; Steiner DF; Ho C; Gomez AJ; Gilks B; Longacre TA; Zehnder JL; Howitt BE; Suarez CJ
    Int J Gynecol Pathol; 2022 Nov; 41(6):541-551. PubMed ID: 34907997
    [TBL] [Abstract] [Full Text] [Related]  

  • 19.
    Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
    Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
    Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 16.